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ABSTRACT 
Purpose 
To determine patient-reported functional outcomes (PROs) in men with prostate cancer 
(PCa) undergoing moderately hypofractionated (H-RT) or conventionally fractionated 
radiotherapy (C-RT) in a national cohort study. 
Patients and Methods 
All men diagnosed with PCa between April 2014 and September 2016 in the English National 
Health Service undergoing C-RT or H-RT were identified in the National Prostate Cancer 
Audit and mailed a questionnaire at least 18 months after diagnosis. Differences in patient-
reported urinary, bowel, sexual, and hormonal function (EPIC-26 domain scores on a 0-100 
scale) and health-related quality of life (EQ5D5L on a 0-1 scale) were estimated using linear 
regression with adjustment for patient, tumour and treatment-related factors in addition to 
gastrointestinal (GI) and genitourinary (GU) baseline function with higher scores 
representing better outcomes. 
Results 
Of the 17,058 men in the cohort, 77% responded: 8,432 men had C-RT (64.2%) and 4,699 H-
RT (35.8%). Men in the H-RT group were older (≥70 years: 67.5% versus 60.9%), fewer men 
had locally advanced disease (56.5% versus 71.3%), were less likely to receive ADT (79.5% 
versus 87.8%) and slightly more men had pre-treatment GU procedures (24.2% versus 
21.2%). H-RT was associated with small increases in adjusted mean EPIC-26 sexual (3.3 
points; 95% CI 2.1-4.5, p<0.001) and hormonal function scores (3.2 points; CI 1.8-4.6, 
p<0.001). These differences failed to meet established thresholds for a clinically meaningful 
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change. There were no statistically significant differences in urinary or bowel function and 
quality of life. 
Conclusion 
This is the first national cohort study comparing functional outcomes after H-RT and C-RT 
reported by patients. These ‘real-world’ results further support the use of H-RT as the 
standard for radiotherapy in men with non-metastatic PCa. 
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INTRODUCTION 
Radical treatments for localised prostate cancer (PCa) are associated with adverse effects. 
External-beam radiation therapy (RT) is an established primary radical treatment option for 
men with localised or locally advanced PCa. A conventionally fractionated RT regimen (C-RT, 
1.8 – 2 Gy doses per fraction) delivered over 7-8 weeks has traditionally been a standard for 
primary PCa. However, a moderately hypofractionated regimen (H-RT) which delivers >2Gy 
over 4 weeks, may offer a therapeutic and economic advantage by delivering an equivalent 
biologically effective dose in a shorter time period without increasing toxic effects.1, 2 
Four recent large randomised clinical trials (RCTs) of modern radiotherapy using intensity-
modulated radiotherapy (IMRT) have demonstrated the comparable efficacy of C-RT and H-
RT without significant differences in 5-year biochemical or clinical failure-free survival.3-7 A 
meta-analysis pooling data from three of these RCTs (each of non-inferiority design) 
demonstrated that H-RT was associated with a significantly increased risk of clinician-
assessed acute (3 month) gastro-intestinal (GI) toxicity (predominantly grade 2 using  
Radiation Therapy Oncology Group criteria), which did not translate into late toxicity 
(median follow-up 5.2 – 6 years). 8  However, H-RT was reported to be associated with an 
increase in late Grade ≥2 genitourinary (GU) toxicity.8  
It is generally accepted that patient-reported outcomes (PROs) detect more reliably adverse 
treatment effects relevant to patients than clinical data.9-11 However, there is limited 
evidence on how PROs in urinary, bowel and sexual function vary by RT regimen. The largest 
RCT to date that reported PROs, the CHHiP study, found no significant differences urinary, 
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bowel and/or sexual functioning between C-RT and H-RT in men with predominantly 
intermediate risk PCa after two years of follow-up.12 
Randomised controlled clinical trials (RCTs) in oncology enrol patients who meet strict 
protocol-specified criteria. Hence, patient populations encountered in clinical practice are 
essentially different from RCT-populations, questioning the representativeness of these 
trials. A ‘real-world’ evidence approach, using data from clinical practice, is increasingly 
employed to complement the information on drug safety and efficacy obtained from 
traditional clinical trials. 
The National Prostate Cancer Audit (NPCA) evaluates the care and outcomes of all men with 
newly diagnosed PCa in the National Health Service (NHS) in England and Wales. The NPCA 
collected PROs for men undergoing radical treatment diagnosed between April 2014 and 
September 2016.13 This national cohort includes more than 13,000 men undergoing C-RT or 
H-RT in England, collected at least 18 months after diagnosis, providing contemporary 
evidence on functional outcomes from large-scale ‘real-world’ clinical practice.14   
 
MATERIALS AND METHODS 
Study design and participants  
All patients diagnosed with PCa in England between 1st April 2014 and 30th September 2016 
as recorded in the English National Cancer Registry and who subsequently underwent RT 
were eligible for inclusion in the patient survey.  
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This study was exempt from NHS Research Ethics Committee approval because it involved 
analysis of de-identified linked data collected for the purpose of service evaluation  
Survey design, administration and data handling 
The NPCA patient questionnaire (Appendix 1) includes the Expanded Prostate Cancer Index 
Composite short-form (EPIC-26), a validated instrument comprising 26 items to measure 
patient function and bother in five domains and the EuroQol EQ-5D-5L.15 
The EPIC-26 produces a validated summary score for each domain ranging from 0 to 100 
with higher scores representing better function.16 Thresholds for a minimal clinically 
important difference (MCID) have been estimated by domain, representing changes 
considered meaningful for patients.17  
The urinary incontinence domain (MCID, 6 points) includes questions related to urinary 
frequency and leakage, and the urinary irritation/obstruction domain (MCID, 5 points) 
focuses on dysuria, haematuria and urinary frequency. The sexual function domain (MCID, 
10-12 points) asks questions related to the quality and frequency of erections. The bowel 
function domain (MCID, 4 points) assesses bowel frequency, urgency, bleeding and pain, 
and the hormonal disturbance domain (MCID, 4 points), includes hot flushes, 
gynaecomastia, low energy and weight change. 
The questionnaire in the second year of the study included three additional adapted EPIC-26 
questions asking men to recall their urinary, bowel and sexual functioning at diagnosis: 
‘Overall, how big a problem was your urinary function/bowel habits/sexual function or lack 
of sexual function for you immediately before you were diagnosed with PCa?’ 
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The EuroQol (EQ-5D-5L) describes generic Health Related Quality of Life (HRQoL) based on 
five domains (mobility, self-care, usual activities, pain/discomfort and anxiety/depression) 
with responses graded at five levels (no/slight/moderate/severe/extreme problems).18 An 
index score on a scale from 0 representing 'death' to 1 'perfect health’ is calculated by 
matching the pattern of the responses against a set of utilities derived from the general UK 
population.19 
Questionnaires were mailed out to patients diagnosed between 1st April 2014 and 30th 
September 2016. Questionnaires were mailed to the homes of all identified men ≥18 
months after diagnosis. Two reminders were sent to non-responders with the final reminder 
≤ 8 weeks after the first mail out. 
Survey response data were linked to records from the NPCA. This includes information on 
age at diagnosis, ethnicity, tumour characteristics according to TNM scores, Gleason biopsy 
score, pre-treatment PSA and receipt of androgen deprivation therapy (ADT) from the 
English National Cancer Registration and Analysis Service. 20 The survey questionnaire 
provided the data on comorbidities. Information on socioeconomic deprivation status was 
obtained from the Hospital Episode Statistics (HES), which records all admissions to English 
NHS providers.21 The national Radiotherapy Dataset (RTDS), which records radiotherapy 
activity in each radiotherapy centre provided information on the RT treatment region 
(prostate bed only/whole pelvis), the use of IMRT (OPCS-4 code ‘X671’), RT doses and 
number of attendances.22 
The Royal College of Surgeons (RCS) Charlson score was used to identify comorbid 
conditions from HES records based on comorbidities coded in the year preceding their 
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prostate cancer diagnosis for the comparison of responders and non-responders only. 23 
Socioeconomic deprivation was defined according to quintiles of the national ranking of the 
Index of Multiple Deprivation (IMD).24 Cancer risk status (low-risk localised, intermediate-
risk localised, locally advanced or advanced cancer) was based on TNM stage, Gleason score, 
and PSA level according to a modified D’Amico algorithm developed by the NPCA.25 
Information about bowel/urinary function baseline function was derived from the presence 
of a GI or GU procedure code in the HES record up to one year prior to RT. The codes 
correspond to previously documented procedure codes used to flag RT treatment toxicity 
(Appendix 2). 26 
Inclusion and exclusion criteria 
18,930 men who were diagnosed with PCa between 1st April 2014 and 30th  September 2016 
and underwent RT were identified from the NPCA database (Figure 1). We excluded patients 
who underwent an unclassified (n=1,159) or other RT regimens (n=431 men) The final study 
cohort comprised 17,058 eligible men undergoing RT with curative intent (Figure 1).  
C-RT or H-RT regimens were defined on the basis of the UK RT dose fractionation guidance 
and the varying dose and fractionation schedules used in recent RCTs. 1, 4-6  C-RT was defined 
on the basis of the regimes most commonly used in UK practice including:  71.4 to 79.5 Gy in 
35 – 40 fractions; 71.4 to 72.5 Gy/32 fractions; 69.4 to 70.5 Gy/35 fractions and 68.4 to 69.5 
Gy/37 fractions . The overall median dose delivered for patients in the CRT cohort was 74 Gy 
in 37 fractions. H-RT was delivered following a moderately hypofractionated regimen with 
defined as 48.9 to 61.1 Gy in 16-20 fractions (median 60 Gy in 16, 19 or 20 fractions). 
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Outcomes 
Primary outcome measures were the five EPIC-26 domain scores and the EQ-5D-5L index 
score. 
Statistical analysis 
Chi-squared tests were used to compare proportions. We used multivariable linear 
regression to estimate differences in outcomes between patients receiving C-RT and H-RT 
with adjustment for age, ethnicity, cancer risk group, year of diagnosis (14/15, 15/16, 
16/17), time from RT to survey (months), comorbidities and IMD as categorical variables and 
ADT, RT type (IMRT), region (prostate only vs whole pelvis), GI and GU baseline procedures 
as binary variables. A random intercept was modelled for each RT centre to adjust for 
clustering within centres. P-values were based on the Wald test.27 
Overall, the completeness of individual clinical data items was ≥90% with the exception of 
PSA at diagnosis (83.2% complete; Table 1). Missing patient response data to individual 
questions were handled in accordance with published guidelines. 15, 18 Completeness of the 
validated composite EPIC-26 scores ranged from 78% (urinary irritation/obstruction domain) 
to 89% (bowel domain), and was 96% for the EQ-5D-5L HRQOL composite score (Table 2). 
Multiple imputation accounted for missing values of the adjustment variables and outcomes 
so that regression models included all 13,131 responders.28 Missing values were replaced 
with 35 sets of plausible values and Rubin’s rules were used to combine estimates and 
obtain adjusted differences with 95% confidence intervals (95% CI).28 
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All reported p-values are two-sided and p<0.05 was considered statistically significant 
without adjustment for multiple comparisons. Data analysis was undertaken using Stata 
version 14. 
RESULTS 
Response rate  
Of the 17,058 included men, 13,131 (77.0%) responded to the survey (Figure 1). Responders 
were likely to be older (≥ 70 years), of white ethnicity, with fewer comorbidities, and were 
more often resident in the least socioeconomically deprived areas (Appendix 3). Overall, 
tumour and treatment characteristics were similar (Appendix 3). Responders who did not 
have a complete score for each of the five EPIC-26 domains were older than responders 
who did have complete scores but other characteristics were similar (Appendix 4). 
Patient population 
Among the 13,131 men who responded to the patient survey, 8,432 (64.2%) had C-RT and 
4,699 (35.8%) had H-RT. IMRT was the predominant RT type (95.2% C-RT and 96.2% H-RT) 
and the use of H-RT increased four-fold during the 30-month study; Table 1). Most men 
underwent RT within 9 months of diagnosis (90.6%), and completed the survey ≥12 months 
after the start of RT (88.6%).  
In the H-RT group men were older (67.5% versus 60.9%, ≥70 years, p<0.001), fewer men had 
locally advanced disease (56.5% versus 71.3%, p<0.001), were less likely to receive ADT 
(79.5% versus 87.8%, p<0.001) and slightly more men had pretreatment urinary procedures 
(24.2 % versus 21.2%, p<0.001) compared with C-RT. Pretreatment bowel procedures were 
similar between groups (5.5% versus 5.2%, p=0.4; Table 1). 
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Patient-reported outcomes according to RT regimen 
Overall EPIC-26 domain and EQ5D5L scores are shown in Table 2. H-RT was associated with 
statistically significantly higher EPIC-26 sexual (adjusted mean difference 3.3 points; 95% CI 
2.1-4.5, p<0.001) and hormonal function scores (adjusted mean difference (3.2 points; 95% 
CI 1.8-4.6, p<0.001) compared with C-RT (Table 3). However, these differences are below 
the established MCID. There was no significant difference in EPIC-26 urinary incontinence, 
urinary obstruction or bowel function scores or in EQ5D5L index scores between H-RT and 
C-RT groups (Table 3). These results were robust to including age and IMD as continuous 
variables in the regression model. 
The effect of key patient, tumour and treatment characteristics on the EPIC-26 scores by 
domain are shown in Appendix 5.  
The frequency of men who indicated that their functioning was a big problem at the time of 
diagnosis was similar between H-RT and C-RT groups: 10.8% (429/3,985) versus 12.2% 
(566/4,623) for urinary, 1.9% (91/3,991) versus 2.3% (90/4,629) for bowel, and 19.5% 
(756/3,870) versus 19.9% (891/4,487) for sexual function, respectively. 
 
DISCUSSION 
Key messages 
In this contemporary, national cohort study of more than 13,000 men, predominantly 
surveyed more than one year after receiving primary C-RT or H-RT with a moderately 
hypofractionated regimen for prostate cancer, there were no clinically significant 
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differences in patient-reported urinary, bowel, sexual or hormonal function or HRQoL. H-RT 
was associated with slightly better sexual and hormonal function scores compared with C-RT 
but these differences were considerably smaller than changes considered meaningful for 
patients. These results reflect the outcomes of recent practice in the English NHS including 
patients diagnosed between 2014 and 2016, the majority of whom (95%) underwent IMRT.  
Comparison with other studies 
There is increasing evidence supporting the use of H-RT in PCa. In the HYPRO trial, combined 
clinician and patient-assessed acute GU toxic effects (≥2 RTOG-EORTC criteria) were similar 
between treatment groups up to 120 days after RT but GI toxicity was increased in the H-RT 
group. The cumulative incidence of severe late grade 3 or above GU toxicity was higher for 
H-RT but the incidence of ≥ grade 3 GI toxicity was similar (median follow-up = 60 
months).3,6The QoL sub-study of the CHHiP trial, the largest RCT to date to report PROs 
following C-RT or H-RT, found no significant differences in patient-reported urinary, bowel 
or sexual functioning or HRQoL between men with clinically localised PCa receiving C-RT (74 
Gy in 37 fractions, n=696) or one of two H-RT schedules (60 Gy in 20 fractions, n=698 or 57 
Gy in 19 fractions, n=706 men) up to 24 months following radiotherapy.12 
Compared with our study, the CHHiP trial had more men with intermediate-risk disease 
(71%), a narrower age-range (64-73 years), and included only 21 of 52 RT centres in England, 
which limits the generalisability of its results. Furthermore, the investigators used different 
instruments to measure functional outcomes (UCLA Prostate Cancer Index [UCLA-PCI] 
initially and the 50-item Expanded Prostate Cancer Index Composite [EPIC-50] later in the 
study), which may have resulted in fewer patients reporting rectal bleeding and faecal 
incontinence than would have been captured using EPIC-50 only.12  
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A recent trial comparing H-RT and C-RT in 962 low-risk prostate-cancer patients found no 
differences in patient-reported outcomes between 6 and 60 months after the start of 
treatment, expect for a statistically but not clinically significant decline in bowel function at 
12 months only.29  
Three smaller RCTs utilising IMRT have also reported no significant differences in patient-
reported urinary, bowel, or sexual functioning measured using the EPIC-50 with short (3-
month) 30 and long-term follow-up (≤ 5 years).31,32 
The toxicity profiles will need to be reviewed in response to the introduction of other 
hypofractionation regimens.33 For example, a phase-III RCT comparing ultra 
hypofractionation and conventional fractionation demonstrated that acute bowel and 
urinary toxicity was more pronounced with ultra-H-RT than with C-RT but that there were 
no differences in 5-year toxicity. 
To our knowledge, our study is the first national population-based prospective study to 
compare PROs and HRQoL in men undergoing C-RT or H-RT. Previous observational studies 
have demonstrated similar clinician-reported GU/GI toxicities in retrospective comparisons 
with C-RT. 34,35 
Methodological considerations 
A key strength of our study is that it reports recent real-world results in patients newly 
diagnosed in the English NHS between 2014 and 2016. Furthermore, a high response rate 
(77%) was achieved. The results reflect outcomes in an unselected national population 
because 95% of men diagnosed with PCa in England undergo treatment in the NHS36,37 
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The characteristics of men who had C-RT and H-RT were similar. In addition, the results from 
the survey are linked to patient level data from the NPCA database so that comparisons of 
PROs could be adjusted for the differences in the characteristics of men who had C-RT or H-
RT. Consequently, the impact of residual ‘confounding by clinical indication’ is likely to be 
small. 
Not all men completed sufficient information to generate an EPIC-26 score for each domain. 
However, the level of missingness did not vary by treatment group which makes it unlikely 
that it has affected differences in the PROs. 
The lack of PROMs immediately before treatment could be considered a limitation in our 
study. However, baseline GI and GU function was measured on the basis of relevant bowel 
and urinary procedures up to one year prior to RT. There were no differences in bowel-
related procedures and only small differences in urinary-related procedures between C-RT 
and H-RT groups, which were controlled for in our analyses.  Furthermore, we did not find 
any differences in recalled urinary, bowel and sexual function immediately before diagnosis. 
Any effect is unlikely to be different between C-RT and H-RT groups which further supports 
the validity of our comparison.  
The use of H-RT increased four-fold in the English NHS during this study period .  Also, the 
type of RT regimen depended on where a patient had his treatment. For men diagnosed in 
the first six months of the diagnosis period, C-RT was the only regimen prescribed in 26 of 
the 52 RT centres in England but for men diagnosed in the last six months of the study H-RT 
was in use by the majority of RT centres (49/52), and the predominant regimen (≥80% of 
patients) in 13 of these centres. This pattern of H-RT use reflects a change in practice that 
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varies by centre over time and reduces the likelihood of patients being allocated to a RT 
regimen based on their individual risk characteristics. 
Non-responders were younger, more often non-white, and more likely to live in less affluent 
areas. However, there were only small differences in response rate by radiotherapy regimen 
(30.2% of non-responders had H-RT compared with 28.1% of responders) and the impact of 
non-response on the findings in this study is likely to be small.  
In our study, almost 90% of men reported their outcomes within two years from the start of 
ratidotherapy. It is possible that differences in outcomes according to type of radiotherapy 
become apparent 5 to 10 years after treatment. However, the results from the RCTs 
comparing C-RT versus H-RT do not demonstrate a consistent increase in late toxicity 
associated with hypofractionation.38 
Clinical Implications 
The benefits of H-RT for patients include greater convenience and shorter total duration of 
treatment. Recently published international, evidence-based guidelines recommend the 
routine use of H-RT with a moderately hypofractionated regimen for localised prostate 
cancer across all risk groups, independent of age, comorbidity, anatomy or baseline urinary 
function.38  
PROs are increasingly being utilised to provide the patient perspective on comparative 
functional and HRQoL outcomes for treatments with similar efficacy and toxicity profiles.39,40 
Our results demonstrating a lack of clinically relevant differences in PROs and HRQoL add to 
the growing evidence base for the use of H-RT in men with non-metastatic PCa.  
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Conclusions  
The results of this contemporary large national cohort study provide evidence that there are 
no clinically significant differences in functional outcomes and HRQoL between men 
receiving H-RT versus C-RT in real-world clinical practice. This supports recent guidelines 
that recommend H-RT with a moderately hypofractionated regimen as the standard of care 
for men with non-metastatic PCa.40 
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Figure 1. Flow chart of men included in the study 
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Table 1. Sociodemographic, tumour &  treatment characteristics for men undergoing 
conventionally fractionated or hypofractionated radiotherapy who responded to the patient 
survey. 
 
 
Conventionally 
fractionated Hypofractionated Total 
 n % n % n % 
Patients 8,432 (64.2%) 4,699 (35.8%) 13,131 
Year of diagnosis      p*<0.001 
Apr 14 – Mar 15 3,751 85.2 652 14.8 4,403  
Apr 15 – Mar 16 3,497 60.7 2,266 29.3 5,763  
Apr 16 – Sept 16 1,184 39.9 1,781 60.1 2,965  
       
Age      p<0.001 
<60 361 4.3 154 3.3 515 3.9 
61-70 2,935 34.8 1,372 29.2 4,307 32.8 
71-80 4,688 55.6 2,795 59.5 7,483 57 
>80 448 5.3 378 8.0 826 6.3 
       
Ethnicity      p=0.015 
White 7,181 96.1 4,010 95.5 11,191 95.9 
Mixed 21 0.3 7 0.2 28 0.2 
Asian/Asian British 83 1.1 76 1.8 159 1.4 
Black/Black British 135 1.8 85 2.0 220 1.9 
Other 49 0.7 23 0.5 72 0.6 
Missing 963 11.4 498 10.6 1,461 11.1 
Comorbidities**     p<0.001 
0 1,609 19.1 815 17.3 2,424 18.5 
1 2,602 30.9 1,361 29.0 3,963 30.2 
≥2 4,221 50.1 2,523 53.7 6,744 51.4 
       
Index of Multiple 
Deprivation      p=0.002 
0 2,022 24.0 1,145 24.4 3,167 24.1 
1 2,144 25.4 1,079 23.0 3,223 24.5 
2 1,836 21.8 992 21.1 2,828 21.5 
3 1,403 16.6 830 17.7 2,233 17.0 
4 1,027 12.2 653 13.9 1,680 12.8 
       
T stage      p<0.001 
1 754 9.1 626 13.6 1,380 10.7 
2 3,318 40.2 2,242 48.6 5,560 43.2 
3 3,973 48.1 1,675 36.3 5,648 43.9 
4 217 2.6 71 1.5 288 2.2 
Missing 170 2.0 85 1.8 255 1.9 
N stage      p<0.001 
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0 7,242 91.3 4,280 97.8 11,522 93.6 
1 693 8.7 97 2.2 790 6.4 
Missing 497 5.9 322 6.9 819 6.2 
Gleason score      p<0.001 
≤6 479 5.9 383 8.4 862 6.8 
7 4,376 53.5 2,938 64.1 7,314 57.3 
≥8 3,330 40.7 1,261 27.5 4,591 36 
Missing 247 2.9 117 2.5 364 2.8 
       
PSA (ng/ml)      p<0.001 
<10 2,494 36.7 1,841 46.3 4,335 40.2 
10-20 2,039 30.0 1,254 31.5 3,293 30.5 
>20 2,270 33.4 885 22.2 3,155 29.3 
Missing 1,629 19.3 719 15.3 2,348 17.9 
       
Risk group     p<0.001 
Locally advanced 5,927 71.3 2,610 56.5 8,537 66 
Intermediate 2,336 28.1 1,951 42.2 4,287 33.1 
Low risk 53 0.6 58 1.3 111 0.9 
Missing 116 1.4 80 1.7 196 1.5 
       
RT modality     p=0.006 
3D conformal 408 4.8 179 3.8 587 4.5 
IMRT 8,024 95.2 4,520 96.2 12,544 95.5 
       
RT treatment region    p<0.001 
Prostate and/or 
seminal vesicles 6,819 82.0 4,327 93.1 11,146 86.0 
Whole pelvis incl. 
lymph nodes 1,499 18.0 319 6.9 1,818 14.0 
Missing 114 1.4 53 1,.1 167 1.3 
       
Hormonal treatment    p<0.001 
No 1,031 12.2 964 20.5 1,995 15.2 
Yes 7,401 87.8 3,735 79.5 11,136 84.8 
       
Pretreatment urinary procedure    p<0.001 
No 6,641 78.8 3,563 75.8 10,204 77.7 
Yes 1,791 21.2 1,136 24.2 2,927 22.3 
       
Pretreatment bowel procedure    p=0.4 
No 7,994 94.8 4,440 94.5 12,434 94.7 
Yes 438 5.2 259 5.5 697 5.3 
       
Time from RT to survey     p<0.001 
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6-12 months 871 10.3 629 13.4 1,500 11.4 
12-18 months 4,251 50.4 3,081 65.6 7,332 55.8 
18-24 months 1,979 23.5 787 16.8 2,766 21.1 
>=24 months 1,331 14.7 202 4.3 1,533 11.7 
Time from diagnosis to RT     p<0.001 
<=6  months 5,280 62.4 2,963 63.1 8,223 62.6 
6-9 months 2,446 29.0 1,185 25.2 3,631 28.0 
>=9 months 726 8.6 551 11.7 1,277 9.7 
       
   *p-value from chi-squared testsAbbreviations: PSA = prostate specific antigen; RT = radiotherapy 
**The survey questionnaire provided the data on comorbidities 
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Table 2. Patient reported outcomes for men undergoing conventionally fractionated or 
hypofractionated radiotherapy – EPIC-26 summary scores for urinary incontinence, urinary 
obstructive/irritative, sexual, bowel and hormonal domains and EQ5D5L index scores for health-
related quality of life based on five domains (mobility, self-care, usual activities, pain/discomfort 
and anxiety/depression).  
 
 Conventionally 
fractionated 
Hypofractionated 
No. of patients 8,432 (22.9%) 4,699 (77.1%) 
EPIC-26:overall domain scores 
Urinary (incontinence)  
Mean (SD) 86.7 (18.8) 85.5 (20.0) 
Missing 1,113 (13.2%) 653 (13.8%) 
Urinary (obstructive/irritative)  
Mean (SD) 86.7 (14.7) 85.2 (16.3) 
Missing 1,637 (19.4%) 985 (21.0%) 
Sexual   
Mean (SD) 17.0 (20.7) 19.7 (23.0) 
Missing 659 (7.8%) 423 (9.0%) 
Bowel   
Mean (SD) 85.7 (18.4) 86.2 (18.3) 
Missing 1,218 (14.4%) 700 (14.9%) 
Hormonal   
Mean (SD) 69.2 (23.4) 73.0 (22.9) 
Missing 1,001 (11.9%) 638 (13.6%) 
EQ-5D    
Overall score   
Mean (SD) 0.84 (0.19) 0.84 (0.19) 
Missing 223 (2.6%) 157 (3.3%) 
Abbreviations: EPIC-26 = Expanded Prostate Cancer Index Composite short-form; SD = standard deviation 
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Table 3. Relationship between patient-reported outcomes and type of radiotherapy regimen: 
unadjusted and adjusted* differences in EPIC-26 domain scores** and EQ5D-5L score for men 
undergoing conventionally fractionated or hypofractionated radiotherapy.  
 
 Unadjusted difference (95% CI) 
H-RT vs C-RT, p value  
Adjusted difference  (95% CI)  
H-RT vs C-RT, p value  
No. of patients   
EPIC-26 
Urinary (incontinence) MCID = 6-9  
 -1.31 (-2.01, -0.61), p<0.001 -0.46 (-1.25, 0.34), p=0.26 
   
Urinary (obstructive/irritative) MCID = 5-7  
 -1.38 (-2.03, -0.72), p<0.001 -0.71 (-1.54, 0.13), p=0.098 
 
   
Sexual MCID = 10-12  
 2.67 (1.88, 3.46), p<0.001 3.32 (2.11, 4.53), p<0.001 
↑ Hypofractionated RT 
   
Bowel MCID = 4-6  
 0.45 (-0.27, 1.16), p=0.22 0.97 (-0.15, 2.08), p=0.09 
 
   
Hormonal MCID = 4-6  
 3.15 (2.26, 4.04), p<0.001 3.20 (1.83, 4.57), p<0.001 
↑ Hypofractionated RT 
   
EQ5D-5L    
   
 0.002 (-0.005, 0.009), p=0.50 0.0006 (-0.006, 0.008), p=0.87 
   
*Multiple imputation by chained equations accounted for missing values of the adjustment variables and 
outcomes so that the multivariable linear regression model included all 10,206 men.  Risk adjustment variables 
include diagnosis year, age, ethnicity, socioeconomic deprivation (IMD), number of comorbities, IMRT, 
radiotherapy region, disease status, time from radiotherapy to survey (months), hormone. 
 
** MCID = minimal clinically important difference in EPIC-26 scores (Skolarus et al. 2015). The EPIC-26 urinary 
incontinence domain (MCID, 6 points) includes questions related to urinary frequency and leakage, and the 
urinary irritation/obstruction domain (MCID, 5 points) focuses on dysuria, haematuria and urinary frequency. 
The sexual function domain (MCID, 10-12 points) asks questions related to the quality and frequency of 
erections. The bowel function domain (MCID, 4 points) assesses bowel frequency, urgency, bleeding and pain. 
The fifth domain, hormonal disturbance (MCID, 4 points), includes hot flushes, gynaecomastia, low energy and 
weight change.   
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Abbreviations: H-RT = hypofractionated radiotherapy; C-RT = conventionally fractionated radiotherapy;  EPIC-
26 = Expanded Prostate Cancer Index Composite short-form; CI = confidence interval; IMD = Index of Multiple 
Deprivation 
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Appendix 1. NPCA Patient Survey 
https://www.npca.org.uk/content/uploads/2019/12/NPCA-Patient-Survey_051219.pdf 
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Appendix 2 (a) Genitourinary and (b) gastrointestinal procedures up to one year prior to 
treatment.1  
 
2a. Genitourinary procedures 
OPCS-4 code2 Description 
H20.1/2/3/4/6/8/9 
H21.2 
Therapeutic colonoscopy 
H22.1/9 Diagnostic colonoscopy +/- biopsies 
H23.1-3/8/9 
H24.2/8 
Therapeutic fibreoptic sigmoidoscopy of lower bowel 
H25.1/8/9 
 
Diagnostic fibreoptic sigmoidoscopy of lower bowel +/- biopsies 
H26.7 
 
Therapeutic rigid sigmoidoscopy of lower bowel 
H28.9 Diagnostic rigid sigmoidoscopy of lower bowel +/- biopsies 
H62.6 Proctoscopy 
 
2b. Gastrointestinal procedures 
OPCS-4 code2 Description 
M44.4/8 Other endoscopic operations on bladder 
M45.5 Examination of bladder using rigid cystoscopy 
M45.9 Unspecified endoscopic examination of bladder 
M47.1 Urethral irrigation of bladder 
M47.8/9 Other specified urethral catheterisation of bladder 
M64.8 Other specified open operations on outlet of male bladder 
M65.1-5 Endoscopic resection of prostate  
M65.8/9 Other specified endoscopic resection of outlet of male bladder 
M66.2 Endoscopic incision of outlet of male bladder 
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M66.8/9 Other specified therapeutic endoscopic operations on outlet of male bladder 
M76.3 Optical urethrotomy 
M76.4 Endoscopic dilation of urethra 
M76.8/9 Other therapeutic endoscopic operations on urethra 
M79.2 Dilation of urethra  
M79.3/4 Internal urethrotomy  
M64.2/3/6 Implantation of artificial urinary sphincter/prosthetic collar into outlet of male bladder 
 
1GI and GU procedures previously reported in Sujenthiran A, Nossiter J, Charman SC, Parry M, Dasgupta P, van 
der Meulen J, et al. National Population-Based Study Comparing Treatment-Related Toxicity in Men Who 
Received Intensity Modulated Versus 3-Dimensional Conformal Radical Radiation Therapy for Prostate Cancer. 
Int J Radiat Oncol Biol Phys 2017;99: 1253-60. 
2 OPCS-4 classification of interventions and procedures (version 4). 
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Appendix 3. Sociodemographic, tumour & radiotherapy treatment characteristics of responders 
and non-responders to the patient survey. 
 Non-responders Responders Total 
 n % n % n % 
Patients 3,927 (23.0%) 13,131 (77.0%) 17,058 
Age       
<60 352 9.0 515 3.9 867 5.1 
61-70 1,410 35.9 4,307 32.8 5,717 33.5 
71-80 1,953 49.7 7,483 57 9,436 55.3 
>80 212 5.4 826 6.3 1,038 6.1 
Ethnicity       
White 3,134 88.5 11,191 95.9 14,325 94.2 
Mixed 21 0.6 28 0.2 49 0.3 
Asian/Asian British 145 4.1 159 1.4 304 2.0 
Black/Black British 186 5.3 220 1.9 406 2.7 
Other 55 1.6 72 0.6 127 0.8 
Missing 386 9.8 1,461 11.1 1,847 10.8 
       
Comorbidities*      
0 2,819 71.8 10,240 78 13,059 76.6 
1 749 19.1 2,012 15.3 2,761 16.2 
≥2 359 9.1 879 6.7 1,238 7.3 
       
Index of Multiple Deprivation 
0 674 17.2 3,167 24.1 3,841 22.5 
1 797 20.3 3,223 24.5 4,020 23.6 
2 802 20.4 2,828 21.5 3,630 21.3 
3 820 20.9 2,233 17.0 3,053 17.9 
4 834 21.2 1,680 12.8 2,514 14.7 
       
T stage       
1 426 11.1 1,380 10.7 1,806 10.8 
2 1,705 44.4 5,560 43.2 7,265 43.5 
3 1,634 42.5 5,648 43.9 7,282 43.6 
4 76 2.0 288 2.2 364 2.2 
Missing 86 2.2 255 1.9 341 2.0 
       
N stage       
0 3,431 93.7 11,522 93.6 14,953 93.6 
1 230 6.3 790 6.4 1,020 6.4 
Missing 266 6.8 819 6.2 1,085 6.4 
       
Gleason score       
≤6 299 7.8 862 6.8 1,161 7.0 
7 2,210 58.0 7,314 57.3 9,524 57.4 
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≥8 1,304 34.2 4,591 36.0 5,895 35.6 
Missing 114 2.9 364 2.8 478 2.8 
PSA (ng/ml)       
<10 1,259 38.9 4,335 40.2 5,594 39.9 
10-20 1,025 31.6 3,293 30.5 4,318 30.8 
>20 955 29.5 3,155 29.3 4,110 29.3 
Missing 688 17.5 2,348 17.9 3,036 17.8 
       
Risk group      
Locally advanced 2,511 65 8,537 66 11,048 65.8 
Intermediate 1,305 33.8 4,287 33.1 5,592 33.3 
Low risk 45 1.2 111 0.9 156 0.9 
Missing 66 1.7 196 1.5 262 1.5 
       
RT modality      
3D conformal 194 4.9 587 4.5 781 4.6 
IMRT 3,733 95.1 12,544 95.5 16,277 95.4 
       
RT treatment region     
Prostate and/or seminal 
vesicles 3,348 86.2 11,146 86 14,494 86 
Whole pelvis incl. lymph 
nodes 538 13.8 1,818 14.0 2,356 14.0 
Missing 41 1.0 167 1.3 208 1.2 
       
Hormonal treatment     
No 735 18.7 1,995 15.2 2,730 16.0 
Yes 3,192 81.3 11,136 84.8 14,328 84.0 
       
Pretreatment urinary procedure     
No 3,013 76.7 10,204 77.7 13,217 77.5 
Yes 914 23.3 2,927 22.3 3,841 22.5 
       
Pretreatment bowel procedure     
No 3,710 94.5 12,434 94.7 16,144 94.6 
Yes 217 5.5 697 5.3 914 5.4 
       
RT regimen      
Standard 2,401 61.1 8,432 64.2 10,833 63.5 
Hypofractionated 1,526 38.9 4,699 35.8 6,225 36.5 
*The Royal College of Surgeons (RCS) Charlson score was used to identify comorbid conditions 
from HES records based on comorbidities coded in the year preceding their prostate cancer 
diagnosis for the comparison of non-responders and responders  
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Appendix 4.  Patient characteristics for men with complete versus incomplete EPIC-26 information 
for each of the five functional domains (urinary incontinence, urinary irritative, 
sexual/bowel/hormonal function). 
 
 Complete EPIC-26 Incomplete Total 
 n % n % n  
Urinary (incontinence)    
Patients 11,365 (86.6%) 1,766 (13.4%) 13,131 
Age       
<60 478 4.2 37 2.1 515 3.92 
61-70 3,859 34.0 448 25.4 4,307 32.8 
71-80 6,356 55.9 1,127 63.8 7,483 57.0 
>80 672 5.9 154 8.7 826 6.3 
       
Comorbidities      
0 2,123 18.7 301 17.0 2,424 18.5 
1 3,429 30.2 534 30.2 3,963 30.2 
≥2 5,813 51.2 931 52.7 6,744 51.4 
       
Risk group      
Locally advanced 7,384 66.0 1,153 66.2 8,537 66.0 
Intermediate 3,710 33.2 577 33.1 4,287 33.1 
Low risk 98 0.9 13 0.8 111 0.9 
Missing 173  23  196  
       
Urinary (obstructive/irritative) function 
Patients 10,509 (80.0%) 2,622 (20.0%) 13,131 
Age       
<60 448 4.3 67 2.6 515 3.92 
61-70 3,651 34.7 656 25.0 4,307 32.8 
71-80 5,834 55.5 1,649 62.9 7,483 57.0 
>80 576 5.5 250 9.5 826 6.3 
       
Comorbidities*      
0 1,970 18.7 475 17.3 2,424 18.5 
1 3,206 30.5 757 28.9 3,963 30.2 
≥2 5,333 50.8 1,411 53.8 6,744 51.4 
       
Risk group      
Locally advanced 6,809 65.9 1,728 66.6 8,537 66.0 
Intermediate 3,439 33.3 848 32.7 4,287 33.1 
Low risk 92 0.9 19 0.7 111 0.9 
Missing 169  27  196  
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Sexual function 
Patients 12,049 (91.8%) 1,082 (8.2%) 13,131 
Age       
<60 449 4.1 16 1.5 515 3.92 
61-70 4,089 33.9 218 20.2 4,307 32.8 
71-80 6,773 56.2 710 65.6 7,483 57.0 
>80 688 5.7 138 12.8 826 6.3 
       
Comorbidities      
0 2,199 18.3 225 20.8 2,424 18.5 
1 3,618 30.0 345 31.9 3,963 30.2 
≥2 6,232 51.7 512 47.3 6,744 51.4 
       
Risk group      
Locally advanced 7,803 68.7 734 65.8 8,537 66.0 
Intermediate 3,959 33.4 328 30.7 4,287 33.1 
Low risk 104 0.9 7 0.7 111 0.9 
Missing 183  13  196  
       
Bowel function 
Patients 11,213 (85.4%) 1,918 (14.6%) 13,131 
Age       
<60 468 4.2 47 2.5 515 3.92 
61-70 3,853 34.4 454 23.7 4,307 32.8 
71-80 6,254 55.8 1,229 64.1 7,483 57.0 
>80 638 5.7 188 9.8 826 6.3 
       
Comorbidities*      
0 2,079 18.5 345 18.0 2,424 18.5 
1 3,415 30.5 548 28.6 3,963 30.2 
≥2 5,719 51.0 1,025 53.4 6,744 51.4 
       
Risk group      
Locally advanced 7,309 66.1 1,228 65.2 8,537 66.0 
Intermediate 3,645 33.0 642 34.1 4,287 33.1 
Low risk 96 0.9 15 0.8 111 0.9 
Missing 163  33  196  
       
Hormonal function 
Patients 11,492 (85.4%) 1,639 (14.6%) 13,131 
Age       
<60 485 4.2 30 1.8 515 3.92 
61-70 3,937 34.3 370 22.6 4,307 32.8 
71-80 6,425 55.9 1,058 64.6 7,483 57.0 
>80 645 5.6 181 11.0 826 6.3 
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Comorbidities*      
0 2,127 18.5 297 18.1 2,424 18.5 
1 3,493 30.4 470 28.7 3,963 30.2 
≥2 5,872 51.1 872 53.2 6,744 51.4 
       
Risk group      
Locally advanced 7,497 66.2 1,040 64.4 8,537 66.0 
Intermediate 3,730 33.0 557 34.5 4,287 33.1 
Low risk 93 0.8 18 1.1 111 0.9 
Missing 172  24  196  
       
 
* The survey questionnaire provided the data on comorbidities 
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Appendix 5. The effect of key patient characteristics, risk group, treatment factors and pre-treatment GI/GU on the EPIC-26 scores for urinary, sexual, 
bowel, or hormone function – mean adjusted difference and 95% CI* 
 
More advanced disease and higher socioeconomic deprivation status were associated with lower hormonal domain scores (p<0.001). Conversely, older age 
was associated with higher EPIC-26 scores for hormone function (p<0.001). Increasing age (p<0.001) and more advanced disease (p<0.001) were associated 
with lower sexual function scores. Pre-treatment GU procedures (p<0.001) were associated with lower urinary incontinence scores and pre-treatment GI 
procedures (p<0.001) with lower bowel function scores. 
 
 Urinary (incont.) 
MCID** = 6-9 
Urinary (obst./irrit.) 
MCID=5-7 
Sexual 
MCID=10-12 
Bowel 
MCID=4-6 
Hormonal 
MCID=4-6  
Patient characteristics 
Age 
<60 
61-70 
71-80 
>80 
p<0.001 
0 
2.4 (0.57, 4.31) 
1.51 (-0.45, 3.47) 
-1.40 (-3.66, 0.86) 
p<0.001 
0 
4.20 (2.56, 5.84) 
3.93 (2.05, 5.82) 
3.28 (0.98, 5.60) 
p<0.001 
0 
-1.88 (-3.95, -0.17) 
-6.77 (-8.82, -4.73) 
-9.57 (-11.78, -7.35) 
p<0.001 
0 
5.55 (3.47, 7.64) 
5.72 (3.60, 7.88) 
4.78 (2.53, 7.04) 
p<0.001 
0 
7.92 (5.98, 9.87) 
11.26 (9.55, 12.97) 
12.07 (9.56, 14.59) 
Ethnicity 
White 
Mixed 
Asian 
Black 
Other 
p=0.003 
0 
-2.98 (-10.58, 4.61) 
-4.57 (-7.58, -1.55) 
-3.86 (-7.04, 0.68) 
-0.70 (-5.09, 3.68) 
p<0.001 
0 
-5.19 (-11.78, 1.40) 
-7.61 (-10.86, -4.36) 
-6.04 (-9.14, -2.95) 
-2.53 (-6.63, 1.56) 
p<0.001 
0 
5.08 (-3.40, 13.52) 
2.04 (-1.24, 5.32) 
8.40 (5.42, 11.32) 
3.44 (-2.71, 9.58) 
p=0.55 
0 
2.78 (-4.00, 9.57) 
-1.68 (-4.72, 1.37) 
0.86 (-2.40, 4.12) 
0.44 (-4.62, 5.52) 
p=0.16 
0 
-0.47 (-10.37, 9.43) 
-4.20 (-8.61, 0.30) 
-2.30 (-5.73, 1.21) 
3.75 (-1.59, 9.10) 
Comorbidities*** 
0 
1 
p=0.001 
0 
-1.61 (-2.51, -0.72) 
p<0.001 
0 
-1.10 (-1.958, -0.25) 
p<0.001 
0 
-2.44 (-3.40, -1.48) 
p<0.001 
0 
-1.37 (-2.41, -0.32) 
p=0.06 
0 
-0.77 (-1.98, 0.46) 
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≥2 -1.39 (-2.66, -1.26) -2.25 (-3.36, -1.14) -1.6 (-2.90, -0.36) -2.7 (-4.14, -1.33) -2.65 (-4.86, -0.44) 
IMD 
1 (least deprived) 
2 
3 
4 
5 (most deprived) 
p<0.001 
0 
-0.11 (-1.10, 0.85) 
-1.28 (-2.17, 0.39) 
-2.63 (-3.71, -1.56) 
-4.07 (-5.41, -2.74) 
p<0.001 
0 
-0.48 (-1.32, 0.37) 
-2.03 (-2.90, -1.153) 
-2.75  (-3.76, -1.74) 
-4.18 (-5.945, -2.91) 
p<0.001 
0 
-0.23 (-1.33, 0.87) 
-1.96 (-3.12, -0.79) 
-2.45 (-3.69, -1.21) 
-3.78 (-4.89, -2.67) 
p<0.001 
0 
-0.09 (-1.07, 0.90) 
-0.80 (-2.01, 0.41) 
-1.94 (-3.04, 0.83) 
-2.8 (-4.04, -1.57) 
p<0.001 
0 
-1.22 (-2.44, -0.13) 
-2.50 (-3.80, -1.20) 
-3.29 (-4.55, -2.02) 
-5.98 (-7.52, -4.21) 
Risk group 
Low 
Intermediate 
Locally advanced 
p=0.12 
0 
-2.33 (-4.79, 0.13) 
-2.96 (-5.74,-0.17) 
p=0.001 
0 
3.29 (-5.97, 0.62) 
-4.51 (-7.33, -0.70) 
p<0.001 
0 
-9.20 (-15.58, -2.81) 
-15.50 (-10.80, -9.09) 
p=0.46 
0 
-2.31 (-6.58, 1.94) 
-2.68 (-7.13, 1.78) 
p<0.001 
0 
-8.25 (-13.27, -3.22) 
-13.09 (-18.28, -7.90) 
Treatment information 
EBRT regimen 
C-RT 
H-RT 
p=0.26 
0 
-0.46 (-1.25, 0.34) 
p=0.10 
0 
-0.71 (-1.55, 0.13) 
p<0.001 
0 
3.32 (2.11, 4.53) 
p=0.0.09 
0 
0.97 (-0.15, 2.08) 
p<0.001 
0 
3.20 (1.83, 4.57) 
ADT 
No 
Yes 
p=0.12 
0 
0.54 (-0.38, 1.45) 
p=0.79 
0 
0.12 (-0.74, 0.97) 
p<0.001 
0 
-2.88 (-3.97, -1.79) 
p=0.08 
0 
0.81 (-0.11, 1.72)   
p<0.001 
0 
-2.19 (-3.30, -1.09) 
IMRT 
No 
Yes 
p=0.38 
0 
0.66 (-0.18, 1.50) 
p=0.70 
0 
0.34 (-1.23, 1.92) 
p=0.30 
0 
-0.89 (-0.80, 2.60) 
p=0.45 
0 
0.70 (-1.09, 2.49) 
p=0.70 
0 
0.39 (-1.59, 2.37) 
RT region 
Prostate only 
p=0.86 
0 
p=0.07 
0 
p<0.001 
0 
p=0.24 
0 
p=0.01 
0 
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         Whole pelvis -0.41 (-1.44, 0.61) 0.22 (-0.66, 1.10) -3.18 (-4.40, -1.97) 0.70 (-0.48, 1.89) -2.17 (-3.91, 0.44) 
Pre-treatment procedures 
GI procedure 
No 
Yes 
P<0.001 
0 
-3.07 (-4.48, 1.67) 
p=0.89 
0 
-3.50 (-4.91, -2.08) 
p=0.55 
0 
-0.50 (-2.10, 1.11) 
p<0.001 
0 
-4.76 (-6.66, -2.87)   
p=0.17 
0 
-2.09 (-3.80, 0.37) 
GU procedure 
No 
Yes 
P<0.001 
0 
-4.08 (-4.95, -3.21) 
p=0.89 
0 
-2.98 (-3.75, -2.21) 
p<0.001 
0 
-2.10 (-2.96, -1.25) 
p<0.001 
0 
-1.98 (-2.85, -1.11)   
p<0.001 
0 
-1.81 (-2.82, 0.80) 
*Multiple imputation by chained equations accounted for missing values of the adjustment variables and outcomes so that the multivariable linear regression model included all 13,131 
men.  Risk adjustment variables include audit year, age, ethnicity, socioeconomic deprivation (IMD) imd, number of comorbities, IMRT, RT regimen, RT region, disease status, time from 
radiotherapy to survey, hormone use, pre-treatment urinary or bowel procedures. These results are estimated from the regression model in Table 3. 
 
** MCID = minimal clinically important difference in EPIC-26 scores (Skolarus et al. 2015). The EPIC-26 urinary incontinence domain (MCID, 6 points) includes questions related to urinary 
frequency and leakage, and the urinary irritation/obstruction domain (MCID, 5 points) focuses on dysuria, haematuria and urinary frequency. The sexual function domain (MCID, 10-12 
points) asks questions related to the quality and frequency of erections. The bowel function domain (MCID, 4 points) assesses bowel frequency, urgency, bleeding and pain. The fifth 
domain, hormonal disturbance (MCID, 4 points), includes hot flushes, gynaecomastia, low energy and weight change.   
*** Patient-reported comorbidities 
Abbreviations: EBRT = external beam radiation; RT = radiotherapy; H-RT = hypofractionated radiotherapy; C-RT = conventionally fractionated radiotherapy;  EPIC-26 = Expanded Prostate 
Cancer Index Composite short-form; CI = confidence interval; IMD = Index of Multiple Deprivation; ADT = androgen deprivation therapy; GI = gastrointestinal; GU = genitorurinary. 
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